---
document_datetime: 2025-12-02 06:38:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/yentreve.html
document_name: yentreve.html
version: success
processing_time: 0.1204555
conversion_datetime: 2025-12-23 21:37:03.644198
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Yentreve

[RSS](/en/individual-human-medicine.xml/65434)

##### Authorised

This medicine is authorised for use in the European Union

duloxetine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Yentreve](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Yentreve?

Yentreve is a medicine containing the active substance duloxetine. It is available as blue (20 mg) and orange (40 mg) capsules.

## What is Yentreve used for?

Yentreve is used to treat moderate to severe stress urinary incontinence (SUI) in women. SUI is accidental leaks of urine during physical exertion or when coughing, laughing, sneezing, lifting or exercising.

The medicine can only be obtained with a prescription.

## How is Yentreve used?

The recommended dose of Yentreve is 40 mg twice a day. Some patients may benefit from starting treatment at a dose of 20 mg twice a day for two weeks before increasing to 40 mg twice a day, to reduce nausea (feeling sick) and dizziness. The benefit of treatment should be re-assessed at regular intervals. Combining Yentreve with pelvic-floor-muscle training may provide additional benefit.

## How does Yentreve work?

The active substance in Yentreve, duloxetine, is a serotonin-noradrenaline re-uptake inhibitor (SNRI). It works by preventing the neurotransmitters 5-hydroxytryptamine (also called serotonin) and noradrenaline from being taken back up into nerve cells in the brain and spinal cord.

Neurotransmitters are chemicals that allow nerve cells to communicate with one another. By blocking their re-uptake, duloxetine increases the amount of these neurotransmitters in the spaces between these nerve cells, increasing the level of communication between the cells. How duloxetine works in SUI is not clear but it is thought that, by increasing the levels of 5-hydroxytryptamine and noradrenaline at the level of the nerves that control the muscle of the urethra (the tube that leads from the bladder to outside), duloxetine causes a stronger closure of the urethra during urine storage. By closing the urethra more powerfully, Yentreve prevents the unwanted loss of urine during physical stress such as coughing or laughing.

## How has Yentreve been studied?

Yentreve has been studied in a total of 2,850 women with SUI. The four main studies involved 1,913 women and lasted 12 weeks, comparing Yentreve (mostly as 40 mg twice daily) with placebo (a dummy treatment). The main measures of effectiveness were incontinence episode frequency (IEF, the number of episodes of incontinence per week) recorded in patient diaries and the patients' scores on an incontinence-specific quality-of-life questionnaire (I-QOL).

## What benefit has Yentreve shown during the studies?

In all four studies, the patients treated with Yentreve had fewer episodes of incontinence after 12 weeks, with about four or five fewer episodes of incontinence per week, in comparison with the number before the study. The IEF decreased by 52% in the Yentreve group, compared with a decrease of 33% in the placebo-treated group. The I-QOL questionnaire scores were also improved in the Yentreve group compared with the placebo group. Yentreve was more effective than placebo only in patients who had more than 14 incontinence episodes per week (moderate to severe SUI) at the start of the study.

## What is the risk associated with Yentreve?

The most common side effects with Yentreve (seen in more than 1 patient in 10) are nausea, dry mouth, constipation and fatigue (tiredness). For the full list of all side effects reported with Yentreve, see the package leaflet.

Yentreve should not be used in people who may be hypersensitive (allergic) to duloxetine or any of the other ingredients. Yentreve should not be used in patients with certain types of liver disease or with severe kidney disease. Yentreve should not be used with monoamine-oxidase inhibitors (a group of antidepressants), fluvoxamine (another antidepressant), or ciprofloxacin or enoxacin (types of antibiotic). Treatment with Yentreve should not be started in patients with uncontrolled high blood pressure, because of a risk of hypertensive crisis (sudden, dangerously high blood pressure).

## Why has Yentreve been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that Yentreve's benefits are greater than its risks for the treatment of moderate to severe SUI. The Committee recommended that Yentreve be given marketing authorisation.

## Other information about Yentreve

The European Commission granted a marketing authorisation valid throughout the European Union for Yentreve to Eli Lilly Nederland B.V. on 11 August 2004.

Yentreve : EPAR - Summary for the public

English (EN) (37.87 KB - PDF)

**First published:** 18/07/2008

**Last updated:** 18/07/2008

[View](/en/documents/overview/yentreve-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-721)

български (BG) (169.94 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/bg/documents/overview/yentreve-epar-summary-public_bg.pdf)

español (ES) (44.46 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/es/documents/overview/yentreve-epar-summary-public_es.pdf)

čeština (CS) (164.04 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/cs/documents/overview/yentreve-epar-summary-public_cs.pdf)

dansk (DA) (43.96 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/da/documents/overview/yentreve-epar-summary-public_da.pdf)

Deutsch (DE) (44.81 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/de/documents/overview/yentreve-epar-summary-public_de.pdf)

eesti keel (ET) (43.49 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/et/documents/overview/yentreve-epar-summary-public_et.pdf)

ελληνικά (EL) (168.38 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/el/documents/overview/yentreve-epar-summary-public_el.pdf)

français (FR) (44.85 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/fr/documents/overview/yentreve-epar-summary-public_fr.pdf)

italiano (IT) (44.27 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/it/documents/overview/yentreve-epar-summary-public_it.pdf)

latviešu valoda (LV) (166.42 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/lv/documents/overview/yentreve-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (159.57 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/lt/documents/overview/yentreve-epar-summary-public_lt.pdf)

magyar (HU) (155.06 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/hu/documents/overview/yentreve-epar-summary-public_hu.pdf)

Malti (MT) (164.42 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/mt/documents/overview/yentreve-epar-summary-public_mt.pdf)

Nederlands (NL) (43.75 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/nl/documents/overview/yentreve-epar-summary-public_nl.pdf)

polski (PL) (169.35 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/pl/documents/overview/yentreve-epar-summary-public_pl.pdf)

português (PT) (44.43 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/pt/documents/overview/yentreve-epar-summary-public_pt.pdf)

română (RO) (151.41 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/ro/documents/overview/yentreve-epar-summary-public_ro.pdf)

slovenčina (SK) (158.98 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/sk/documents/overview/yentreve-epar-summary-public_sk.pdf)

slovenščina (SL) (149.78 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/sl/documents/overview/yentreve-epar-summary-public_sl.pdf)

Suomi (FI) (43.82 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/fi/documents/overview/yentreve-epar-summary-public_fi.pdf)

svenska (SV) (43.9 KB - PDF)

**First published:**

18/07/2008

**Last updated:**

18/07/2008

[View](/sv/documents/overview/yentreve-epar-summary-public_sv.pdf)

Yentreve : EPAR - Risk-management-plan summary

English (EN) (2.02 MB - PDF)

**First published:** 08/10/2019

**Last updated:** 22/09/2020

[View](/en/documents/rmp-summary/yentreve-epar-risk-management-plan-summary_en.pdf)

## Product information

Yentreve : EPAR - Product Information

English (EN) (546.95 KB - PDF)

**First published:** 15/09/2009

**Last updated:** 09/07/2024

[View](/en/documents/product-information/yentreve-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-72)

български (BG) (638.31 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/bg/documents/product-information/yentreve-epar-product-information_bg.pdf)

español (ES) (562.92 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/es/documents/product-information/yentreve-epar-product-information_es.pdf)

čeština (CS) (605.74 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/cs/documents/product-information/yentreve-epar-product-information_cs.pdf)

dansk (DA) (538.56 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/da/documents/product-information/yentreve-epar-product-information_da.pdf)

Deutsch (DE) (542.22 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/de/documents/product-information/yentreve-epar-product-information_de.pdf)

eesti keel (ET) (531.46 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/et/documents/product-information/yentreve-epar-product-information_et.pdf)

ελληνικά (EL) (654.22 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/el/documents/product-information/yentreve-epar-product-information_el.pdf)

français (FR) (589.85 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/fr/documents/product-information/yentreve-epar-product-information_fr.pdf)

hrvatski (HR) (551.57 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/hr/documents/product-information/yentreve-epar-product-information_hr.pdf)

íslenska (IS) (451.74 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/is/documents/product-information/yentreve-epar-product-information_is.pdf)

italiano (IT) (540.01 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/it/documents/product-information/yentreve-epar-product-information_it.pdf)

latviešu valoda (LV) (567.85 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/lv/documents/product-information/yentreve-epar-product-information_lv.pdf)

lietuvių kalba (LT) (611.21 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/lt/documents/product-information/yentreve-epar-product-information_lt.pdf)

magyar (HU) (616.99 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/hu/documents/product-information/yentreve-epar-product-information_hu.pdf)

Malti (MT) (956.27 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/mt/documents/product-information/yentreve-epar-product-information_mt.pdf)

Nederlands (NL) (515.44 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/nl/documents/product-information/yentreve-epar-product-information_nl.pdf)

norsk (NO) (454.86 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/no/documents/product-information/yentreve-epar-product-information_no.pdf)

polski (PL) (600.88 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/pl/documents/product-information/yentreve-epar-product-information_pl.pdf)

português (PT) (617.4 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/pt/documents/product-information/yentreve-epar-product-information_pt.pdf)

română (RO) (560.03 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/ro/documents/product-information/yentreve-epar-product-information_ro.pdf)

slovenčina (SK) (600.7 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/sk/documents/product-information/yentreve-epar-product-information_sk.pdf)

slovenščina (SL) (635.94 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/sl/documents/product-information/yentreve-epar-product-information_sl.pdf)

Suomi (FI) (522.85 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/fi/documents/product-information/yentreve-epar-product-information_fi.pdf)

svenska (SV) (557.32 KB - PDF)

**First published:**

15/09/2009

**Last updated:**

09/07/2024

[View](/sv/documents/product-information/yentreve-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00001187/202308 17/06/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Yentreve : EPAR - All Authorised presentations

English (EN) (16.6 KB - PDF)

**First published:** 04/12/2006

**Last updated:** 23/03/2016

[View](/en/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-936)

български (BG) (55.25 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/bg/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.05 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/es/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_es.pdf)

čeština (CS) (24.49 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/cs/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (17.07 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/da/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (16.76 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/de/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.13 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/et/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (44.25 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/el/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_el.pdf)

français (FR) (16.31 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/fr/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (39.58 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/hr/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (17.1 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/is/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.7 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/it/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (34.5 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/lv/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (35.14 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/lt/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (23.97 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/hu/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (32 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/mt/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (16.34 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/nl/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (16.29 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/no/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_no.pdf)

polski (PL) (34.69 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/pl/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_pl.pdf)

português (PT) (19.46 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/pt/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_pt.pdf)

română (RO) (33.06 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/ro/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (24.88 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/sk/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (32.38 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/sl/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (16.59 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/fi/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (16 KB - PDF)

**First published:**

04/12/2006

**Last updated:**

23/03/2016

[View](/sv/documents/all-authorised-presentations/yentreve-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Yentreve Active substance duloxetine hydrochloride International non-proprietary name (INN) or common name duloxetine Therapeutic area (MeSH) Urinary Incontinence, Stress Anatomical therapeutic chemical (ATC) code N06AX21

### Pharmacotherapeutic group

Psychoanaleptics

### Therapeutic indication

Yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (SUI).

## Authorisation details

EMA product number EMEA/H/C/000545 Marketing authorisation holder

Eli Lilly Nederland B.V.

Papendorpseweg 83

Marketing authorisation issued 11/08/2004 Revision 29

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Yentreve : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (362.22 KB - PDF)

**First published:** 15/09/2009

**Last updated:** 09/07/2024

[View](/en/documents/procedural-steps-after/yentreve-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Yentreve-H-C-PSUSA-00001187-202308: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/314979/2024

English (EN) (151.03 KB - PDF)

**First published:** 09/07/2024

[View](/en/documents/scientific-conclusion/yentreve-h-c-psusa-00001187-202308-epar-scientific-conclusions-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Yentreve-H-C-545-PSUSA-00001187-201408 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/PRAC/154100/2015

English (EN) (66.08 KB - PDF)

**First published:** 08/07/2015

**Last updated:** 08/07/2015

[View](/en/documents/scientific-conclusion/yentreve-h-c-545-psusa-00001187-201408-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Yentreve-H-C-545-P46-40 : EPAR - Assessment Report

Adopted

Reference Number: EMA/121591/2013

English (EN) (2.11 MB - PDF)

**First published:** 08/03/2013

**Last updated:** 08/03/2013

[View](/en/documents/variation-report/yentreve-h-c-545-p46-40-epar-assessment-report_en.pdf)

Yentreve-H-C-545-P46-33 : EPAR - Assessment Report

Adopted

Reference Number: EMA/18171/2013

English (EN) (467.44 KB - PDF)

**First published:** 17/01/2013

**Last updated:** 17/01/2013

[View](/en/documents/variation-report/yentreve-h-c-545-p46-33-epar-assessment-report_en.pdf)

Yentreve-H-C-A18-652 : EPAR - Scientific Conclusion

Adopted

English (EN) (118.94 KB - PDF)

**First published:** 07/02/2006

**Last updated:** 07/02/2006

[View](/en/documents/scientific-conclusion/yentreve-h-c-a18-652-epar-scientific-conclusion_en.pdf)

## Initial marketing authorisation documents

Yentreve : EPAR - Scientific Discussion

English (EN) (409.1 KB - PDF)

**First published:** 07/02/2006

**Last updated:** 07/02/2006

[View](/en/documents/scientific-discussion/yentreve-epar-scientific-discussion_en.pdf)

Yentreve : EPAR - Procedural steps taken before authorisation

English (EN) (95.99 KB - PDF)

**First published:** 07/02/2006

**Last updated:** 07/02/2006

[View](/en/documents/procedural-steps/yentreve-epar-procedural-steps-taken-authorisation_en.pdf)

#### More information on Yentreve

- [EMEA-000420-PIP01-10 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000420-pip01-10)
- [Observational Study to Assess Maternal and Fetal Outcomes Following Exposure to Duloxetine (F1J-MC-B059) - post-authorisation study](https://catalogues.ema.europa.eu/study/44527)
- [Stress Urinary Incontinence and Suicidality Seen in the United Kingdom General Practice Research Database (F1J-MC-B056) - post-authorisation study](https://catalogues.ema.europa.eu/study/21190)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 09/07/2024

## Share this page

[Back to top](#main-content)